FOCIS Translational Immunology Update Workspace
Note: If you are a clinical trial contributor, please click on the Clinical Trial Contributions link in the right side bar.
Topic Selection & Scheduling
1. Select the Edit tab at the top of the page.
2. Place an X next to the topic and under the month when you would like the article to appear.
3. When finished, click Save at the bottom of the page and log out in the upper right corner.
| |
Sept.
2010 |
Nov. 2010 |
Jan. 2011 |
March
2011 |
May
2011 |
June
2011 |
Aug. 2011 |
Oct. 2011 |
|
Science Behind Novel Immune Therapies – Scott Plevy
|
|
|
|
|
|
|
|
|
|
Th17 based therapies (anti-Il-12/23, anti-IL-17)
|
x |
|
|
|
|
|
|
|
|
Anti-integrins
|
|
|
|
x |
|
|
|
|
|
Anti-CD3
|
|
|
x |
|
|
|
|
|
|
Jak inhibitors
|
|
|
|
|
|
|
|
x |
|
Costimulation (CTLA4 Ig, anti-CTLA4)
|
|
|
|
|
|
|
x |
|
|
B cell depletion/inhibition
|
|
|
|
|
|
x |
|
|
|
TNF inhibitors – mechanism of action
|
|
x |
|
|
|
|
|
|
|
Inflammasome based therapeutics
|
|
|
|
|
x |
|
|
|
|
Basic Science Section – Andrew Lichtman
|
|
|
|
|
|
|
|
|
|
Recognition of cell damage by innate immune receptors
|
|
|
|
|
|
|
|
|
|
The inflammasome
|
x |
|
|
|
|
|
|
|
|
Viral recognition by the innate immune system
|
|
|
|
|
|
x |
|
|
|
TLRs and autoimmunity
|
|
|
|
|
|
|
|
|
|
Tolerogenic dendritic cells
|
|
|
|
|
|
|
|
|
|
Functions and mechanism of action of CTLA-4
|
|
x |
|
|
|
|
|
|
|
Th17 cells in inflammatory diseases
|
|
|
|
x |
|
|
|
|
|
Mucosal immunity and the microbiome
|
|
|
x |
|
|
|
|
|
|
Sphingosine 1 phosphate and lymphocyte migration
|
|
|
|
|
|
|
|
|
|
Follicular helper T cells
|
|
|
|
|
x |
|
|
|
|
Human Immunophenotyping – Holden Maecker
|
|
|
|
|
|
|
|
|
|
Methods to identify antigen-specific T cells
|
x |
|
|
|
|
|
|
|
|
How do you tell a Treg? (markers and strategies for identifying regulatory T cells)
|
|
x |
|
|
|
|
|
|
|
Dendritic cell subsets: how many and how to gate them?
|
|
|
x |
|
|
|
|
|
|
Instrument setup and QC: what is essential?
|
|
|
|
x |
|
|
|
|
|
Reagent stabilization for large, multicenter, and longitudinal studies
|
|
|
|
|
x |
|
|
|
|
Minimizing gating variability in flow cytometry
|
|
|
|
|
|
x |
|
|
|
Mass cytometry and the future of multiparameter flow cytometry
|
|
|
|
|
|
|
x |
|
Comments (0)
You don't have permission to comment on this page.